Trials / Completed
CompletedNCT00283439
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects With Lymphoma.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
Conditions
- Chemotherapy-Induced Thrombocytopenia
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Cancer
- Oncology
- Thrombocytopenia
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AMG 531 | Planned Cohorts: 1. 100 mcg, 2. 300 mcg, 3. 700 mcg, 4. 1000 mcg; Optional Cohorts: 5. cohort expansion, 6. schedule change, 7. new dose |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-05-01
- Completion
- 2008-09-01
- First posted
- 2006-01-30
- Last updated
- 2011-06-20
- Results posted
- 2010-09-13
Source: ClinicalTrials.gov record NCT00283439. Inclusion in this directory is not an endorsement.